What is the long-term trend for Spyre Therapeutics, Inc.'s cash equivalents, gross unrealized gains?

Over 2 years (2023 to 2025), Spyre Therapeutics, Inc.'s cash equivalents, gross unrealized gains has grown at a -100.0% compound annual growth rate (CAGR), from $6K to $0.

Spyre Therapeutics, Inc. SYRE Cash equivalents, gross unrealized gains

Other financials

Income statement

See full

Revenue-—

Operating income-$45.6M+14.8%

Net income-$69.0M-54.1%

EPS (diluted)-$0.74-23.3%

Balance sheet

See full

Cash & equivalents$97.2M+100%

Total debt$4.3M-9.6%

Total equity$670.8M+39.0%

Total assets$764.0M+34.1%

Cash flow

See full

Operating cash flow-$57.4M-40.0%

CapEx-—

Free cash flow-$39.4M-26.8%

Valuation

See full

Market cap$7.67B+307%

Profitability

See full

Operating margin-39,428.9%-49,795pp

Net margin-52,939.7%-61,871pp

FCF margin-3,442.8%-3,807pp

Returns & leverage

See full

Return on equity-31.1%-10.7pp

Debt / equity0.1×+0.1×

Current ratio9×+0.9×

Where this comes from

Reported directly by Spyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept syre:CashEquivalentsUnrealizedGains.

The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Spyre Therapeutics, Inc.'s cash equivalents, gross unrealized gains.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Spyre Therapeutics, Inc.'s cash equivalents, gross unrealized gains?: Spyre Therapeutics, Inc. (SYRE) reported cash equivalents, gross unrealized gains of $0 in Q1 2026.
What is the long-term trend for Spyre Therapeutics, Inc.'s cash equivalents, gross unrealized gains?: Over 2 years (2023 to 2025), Spyre Therapeutics, Inc.'s cash equivalents, gross unrealized gains has grown at a -100.0% compound annual growth rate (CAGR), from $6K to $0.